These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 28262558)

  • 1. Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells.
    Tumber A; Nuzzi A; Hookway ES; Hatch SB; Velupillai S; Johansson C; Kawamura A; Savitsky P; Yapp C; Szykowska A; Wu N; Bountra C; Strain-Damerell C; Burgess-Brown NA; Ruda GF; Fedorov O; Munro S; England KS; Nowak RP; Schofield CJ; La Thangue NB; Pawlyn C; Davies F; Morgan G; Athanasou N; Müller S; Oppermann U; Brennan PE
    Cell Chem Biol; 2017 Mar; 24(3):371-380. PubMed ID: 28262558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a Linked Jumonji Domain of the KDM5/JARID1 Family of Histone H3 Lysine 4 Demethylases.
    Horton JR; Engstrom A; Zoeller EL; Liu X; Shanks JR; Zhang X; Johns MA; Vertino PM; Fu H; Cheng X
    J Biol Chem; 2016 Feb; 291(6):2631-46. PubMed ID: 26645689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KDOAM-25 Overcomes Resistance to MEK Inhibitors by Targeting KDM5B in Uveal Melanoma.
    Zhang H; Liu X; Chen Y; Xu R; He S
    Biomed Res Int; 2022; 2022():1556485. PubMed ID: 36212716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies of H3K4me3 demethylation by KDM5B/Jarid1B/PLU1 reveals strong substrate recognition in vitro and identifies 2,4-pyridine-dicarboxylic acid as an in vitro and in cell inhibitor.
    Kristensen LH; Nielsen AL; Helgstrand C; Lees M; Cloos P; Kastrup JS; Helin K; Olsen L; Gajhede M
    FEBS J; 2012 Jun; 279(11):1905-14. PubMed ID: 22420752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The KDM5 family of histone demethylases as targets in oncology drug discovery.
    Rasmussen PB; Staller P
    Epigenomics; 2014 Jun; 6(3):277-86. PubMed ID: 25111482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of in vitro JMJD lysine demethylase candidate substrates via systematic determination of substrate preference.
    Hoekstra M; Biggar KK
    Anal Biochem; 2021 Nov; 633():114429. PubMed ID: 34678252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural analysis of human KDM5B guides histone demethylase inhibitor development.
    Johansson C; Velupillai S; Tumber A; Szykowska A; Hookway ES; Nowak RP; Strain-Damerell C; Gileadi C; Philpott M; Burgess-Brown N; Wu N; Kopec J; Nuzzi A; Steuber H; Egner U; Badock V; Munro S; LaThangue NB; Westaway S; Brown J; Athanasou N; Prinjha R; Brennan PE; Oppermann U
    Nat Chem Biol; 2016 Jul; 12(7):539-45. PubMed ID: 27214403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of potent, selective KDM5 inhibitors.
    Gehling VS; Bellon SF; Harmange JC; LeBlanc Y; Poy F; Odate S; Buker S; Lan F; Arora S; Williamson KE; Sandy P; Cummings RT; Bailey CM; Bergeron L; Mao W; Gustafson A; Liu Y; VanderPorten E; Audia JE; Trojer P; Albrecht BK
    Bioorg Med Chem Lett; 2016 Sep; 26(17):4350-4. PubMed ID: 27476424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Domain architecture and protein-protein interactions regulate KDM5A recruitment to the chromatin.
    Kataria A; Tyagi S
    Epigenetics; 2023 Dec; 18(1):2268813. PubMed ID: 37838974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based design and discovery of potent and selective KDM5 inhibitors.
    Nie Z; Shi L; Lai C; O'Connell SM; Xu J; Stansfield RK; Hosfield DJ; Veal JM; Stafford JA
    Bioorg Med Chem Lett; 2018 May; 28(9):1490-1494. PubMed ID: 29627262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.
    Vinogradova M; Gehling VS; Gustafson A; Arora S; Tindell CA; Wilson C; Williamson KE; Guler GD; Gangurde P; Manieri W; Busby J; Flynn EM; Lan F; Kim HJ; Odate S; Cochran AG; Liu Y; Wongchenko M; Yang Y; Cheung TK; Maile TM; Lau T; Costa M; Hegde GV; Jackson E; Pitti R; Arnott D; Bailey C; Bellon S; Cummings RT; Albrecht BK; Harmange JC; Kiefer JR; Trojer P; Classon M
    Nat Chem Biol; 2016 Jul; 12(7):531-8. PubMed ID: 27214401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance.
    Gale M; Sayegh J; Cao J; Norcia M; Gareiss P; Hoyer D; Merkel JS; Yan Q
    Oncotarget; 2016 Jun; 7(26):39931-39944. PubMed ID: 27224921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drawing a line between histone demethylase KDM5A and KDM5B: their roles in development and tumorigenesis.
    Yoo J; Kim GW; Jeon YH; Kim JY; Lee SW; Kwon SH
    Exp Mol Med; 2022 Dec; 54(12):2107-2117. PubMed ID: 36509829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone H3K4 demethylases are essential in development and differentiation.
    Benevolenskaya EV
    Biochem Cell Biol; 2007 Aug; 85(4):435-43. PubMed ID: 17713579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing histone demethylase inhibitors in cells: lessons learned.
    Hatch SB; Yapp C; Montenegro RC; Savitsky P; Gamble V; Tumber A; Ruda GF; Bavetsias V; Fedorov O; Atrash B; Raynaud F; Lanigan R; Carmichael L; Tomlin K; Burke R; Westaway SM; Brown JA; Prinjha RK; Martinez ED; Oppermann U; Schofield CJ; Bountra C; Kawamura A; Blagg J; Brennan PE; Rossanese O; Müller S
    Epigenetics Chromatin; 2017; 10():9. PubMed ID: 28265301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia induces rapid changes to histone methylation and reprograms chromatin.
    Batie M; Frost J; Frost M; Wilson JW; Schofield P; Rocha S
    Science; 2019 Mar; 363(6432):1222-1226. PubMed ID: 30872526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia induces trimethylated H3 lysine 4 by inhibition of JARID1A demethylase.
    Zhou X; Sun H; Chen H; Zavadil J; Kluz T; Arita A; Costa M
    Cancer Res; 2010 May; 70(10):4214-21. PubMed ID: 20406991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of novel lysine demethylase 5-selective inhibitors by inhibitor-based fragment merging strategy.
    Miyake Y; Itoh Y; Hatanaka A; Suzuma Y; Suzuki M; Kodama H; Arai Y; Suzuki T
    Bioorg Med Chem; 2019 Mar; 27(6):1119-1129. PubMed ID: 30745098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired removal of H3K4 methylation affects cell fate determination and gene transcription.
    Lussi YC; Mariani L; Friis C; Peltonen J; Myers TR; Krag C; Wong G; Salcini AE
    Development; 2016 Oct; 143(20):3751-3762. PubMed ID: 27578789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-talk between Lysine-Modifying Enzymes Controls Site-Specific DNA Amplifications.
    Mishra S; Van Rechem C; Pal S; Clarke TL; Chakraborty D; Mahan SD; Black JC; Murphy SE; Lawrence MS; Daniels DL; Whetstine JR
    Cell; 2018 Aug; 174(4):803-817.e16. PubMed ID: 30057114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.